No abstract

Objective:To describe social participation strategies and resilience in the people affected by the 2017 earthquakes in Mexico.Methods:A cross-sectional study was carried out with 1504 participants from Mexico City, State of Mexico, Oaxaca, Chiapas, Puebla, and Morelos in November and December 2017. A nonprobabilistic convenience sampling method was used to recruit voluntary participants who met the inclusion criteria: age 18 or over and residents in damaged states at the time of the earthquakes. Postearthquake social participation strategies were assessed with the formats used in the postearthquake Chilean survey in 2010. The Spanish-validated version of the resilience scale RS-14 was applied for measuring resilience in the Mexican population.Results:The most frequent social participation strategies were related to emotional support and aid supplying water, food, and clothing. The highest resilience was observed in the state of Oaxaca and in Mexico City. Men, people age 40 or over, and people who defined themselves as indigenous were the most resilient.Conclusions:Factors related to resilience were male gender, age over 40, did not participate in activities of help to the community, no household damage, and belonging to an indigenous community.

Given the variability of previously reported results, this systematic review aims to determine the clinical effectiveness of convalescent plasma employed in the treatment of hospitalized patients with diagnosis of COVID-19.We conducted a systematic review of controlled clinical trials assessing treatment with convalescent plasma for hospitalized patients with a diagnosis of SARS-CoV-2 infection. The outcomes were mortality, clinical improvement, and ventilation requirement.A total of 50 studies were retrieved from the databases. Four articles were finally included in the data extraction, qualitative and quantitative synthesis of results. The meta-analysis suggests that there is no benefit of convalescent plasma compared to standard care or placebo in the reduction of the overall mortality and in the ventilation requirement; but there could be a benefit for the clinical improvement in patients treated with plasma.We can conclude that the convalescent plasma transfusion cannot reduce the mortality or ventilation requirement in hospitalized patients diagnosed with SARS-CoV-2 infection. More controlled clinical trials conducted with methodologies that ensure a low risk of bias are still needed.

Objective. The aim was to assess the clinical effectiveness of drugs used in hospitalized patients with COVID-19 infection. Method. We conducted a systematic review of randomized clinical trials assessing treatment with remdesivir, chloroquine, hydroxychloroquine, lopinavir, ritonavir, dexamethasone, and convalescent plasma, for hospitalized patients with a diagnosis of SARS-CoV-2 infection. The outcomes were mortality, clinical improvement, duration of ventilation, duration of oxygen support, duration of hospitalization), virological clearance, and severe adverse events. Results. A total of 48 studies were retrieved from the databases. Ten articles were finally included in the data extraction and qualitative synthesis of results. The meta-analysis suggests a benefit of dexamethasone versus standard care in the reduction of risk of mortality at day 28; and the clinical improvement at days 14 and 28 in patients treated with remdesivir. Conclusions. Dexamethasone would have a better result in hospitalized patients, especially in low-resources settings. Significance of results. The analysis of the main treatments proposed for hospitalized patients is of vital importance to reduce mortality in low-income countries; since the COVID-19 pandemic had an economic impact worldwide with the loss of jobs and economic decline in countries with scarce resources. Keywords: Drugs; Antivirals; Clinical improvement; Mortality; COVID-19; SARS-CoV2.

El presente documento busca analizar las tendencias de mortalidad por desnutrición y por causas infecciosas en menores de cinco años durante el período 2001-2013 en la Argentina. Para ello se construyeron tasas de mortalidad por cada 100.000 recién nacidos en los menores de 1 año y por cada 100.000 niños en las edades de 1-4 años. Las tendencias se analizaron por modelos de regresión de Poisson. Los principales resultados muestran que las tasas de mortalidad en menores de 1 año y en niños de 1-4 años presentaron una tendencia descendente en los años analizados (p< 0,01), con excepción de la mortalidad por enfermedades infecciosas de origen respiratorio en el grupo de 1-4. La cobertura de seguro de salud del niño se comportó como factor protector para el riesgo de morir (p<0,01). El documento concluye que las tendencias de mortalidad descendieron entre los años 2001-2013, mientras que la cobertura de seguro de salud es un factor protector para esa mortalidad.